Phaseline

Companies › Regenerative Patch Technologies

Regenerative Patch Technologies: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CPCB-RPE1 implant
Retinal pigment epithelium (RPE) cell replacement therapy
–Phase 2Dry Age-related Macular DegenerationDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06557460CPCB-RPE1 implantPhase 2Dry Age-related Macular DegenerationOphthalmologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

NexThera Price Vision Group jCyte NovaSight Emmecell

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.